Fresno hospital system quietly cuts hundreds of nursing supervisor roles
In the Spotlight is a Fresno Bee series that digs into the high-profile local issues that readers care most about. Story idea? Email tips@fresnobee.com.
Fresno's largest healthcare system discreetly slashed hundreds of nursing supervisor positions in recent weeks as part of a staffing shakeup.
Nearly 300 clinical nursing supervisors employed by Community Health System were informed that they had to decide whether to take a pay cut, apply for a leadership position or accept a severance package.
A March 4 letter obtained by The Bee confirms CHS notified Fresno city and county officials about plans to eliminate 285 positions due to the hospital system 'restructuring its operations.' The letter said the layoffs impacted 180 positions at Community Regional Medical Center, as well as 19 positions at Fresno Heart & Surgical Hospital and 86 positions at Clovis Community Medical Center.
The layoffs at CHS took effect May 3, weeks before news broke that the health system agreed to settle a federal probe and pay a $31.5 million fine, raising questions for some staff members.
Last month, CHS entered a massive settlement agreement announced last month by the U.S. Attorney's Office. The settlement addresses allegations that CHS was involved in a multi-year kickback scheme in which hospital executives provided expensive wine, liquor, cigars and meals to physicians in exchange for patient referrals.
CHS denies the settlement was the reason for the staffing changes.
'Community frequently evaluates our care model to assure that we have the right staffing mix to meet changing patient care needs,' Daniel Davis, R.N. division president of hospitals for CHS, said in a statement.
'This shift was driven solely by clinical best practice and patient care needs and was not designed to achieve cost savings,' Davis said.
Any company with 75 or more employees must file a WARN notice if it lays off 50 or more employees in a 30-day period, according to state law.
Hospital spokesperson Mary Lisa Russell said a WARN notice was sent out in early March, as required by law.
However, a spokesperson for the state's Employment Development Department said they had no record of a WARN notice from CHS.
Two nurse supervisors said the 285 impacted employees were forced to apply to new leadership positions, or take a demotion, with the majority taking big pay cuts.
'We were told that these changes had nothing to do with finances. That is incredibly hard to believe,' said one former nursing supervisor who spoke on condition of anonymity due to fear of professional retaliation.
The nursing supervisor said rumors started circulating in February about the elimination of clinical nursing supervisor roles.
She said affected staff met individually with human resources to explore their options — either applying for assistant nurse manager, charge nurse or clinical nurse ladder positions, or accept a severance package. CHS also offered two-year retention bonuses. Most positions offered lower pay than the eliminated supervisor role.
Another nursing supervisor who had worked at Community for more than a decade — who said she loved her job and had no discipline record — accepted a severance package after her position was eliminated. The supervisor said she thinks the restructuring was a cost-saving measure.
She said employees and patient care were sacrificed to pay for leadership's actions. Clinical supervising nurses who accepted other nursing positions have to be retrained on charting and other bedside nurse responsibilities, she said.
'I loved working here, I love my team,' she said.
Davis said CHS developed a new job description for assistant nurse manager, which is a model of clinical leadership and staffing followed by other local hospitals like Kaiser, Kaweah Health and Sutter Health.
'Based on those needs and industry best practice to support nursing at the bedside, we transitioned away from Clinical Nursing Supervisors and toward a combined Assistant Nurse Manager and Charge Nurse model,' Davis said.
Davis said that 247 of the 285 affected nurses transitioned to new roles.
'Only a small percentage chose to separate,' he said.
He also said in the coming months, 'nearly 95% of our workforce will see compensation increases as we continue to implement an organization-wide set of adjustments to align with California's new healthcare minimum wage.'
A new state law signed by Gov. Gavin Newsom in 2023 requires an increase in the minimum wage for workers at several eligible healthcare facilities.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Fourth annual Hallie Grace Memorial Butterfly Ball for EB
SAVANNAH, Ga. (WSAV) — Epidermalysis Bullosa, also known as EB, is a rare genetic condition that affects one in every 20,000 births. Babies diagnosed with this condition usually don't live long lives, and they are often referred to as butterfly babies because their skin is as fragile as a butterfly's wings. Turning grief into triumph is how one family, whose child was diagnosed with a rare genetic skin condition, is honoring her life and legacy. 'To be a lost parent is the worst thing in the world. And I would give anything to make sure nobody else has to ever go through that again,' said mother of Hallie Grace and Executive Director of Heroes for Hallie Grace, INC Anne Davis. It's the fourth annual Hallie Grace Memorial Butterfly Ball for EB. Mom of Hallie Grace Anne Davis, who passed away when she was only three months old from the genetic skin condition, said events like these are important to spread awareness because many don't know what EB is or how it affects families dealing with it. 'When you lose a child, the one thing you want more than anything is for them to be remembered and to know that their life mattered,' Davis said. 'So, our biggest mission, is that we raise awareness, we raise funding all that. But our biggest thing is connecting with the families, making sure that those families know that those children still matter, whether or not they're still here.' The painful skin condition is caused by a missing protein that holds the skin together, so with any sort of touch or heat, it can blister the skin and cause it to fall off. Davis said when doctors told her there was nothing they could do; she made it a goal to make sure another family would never have to experience the pain that they felt that day. 'When we get to know these families and we get to see these families go through this and we know what the diagnosis is, it's like watching a Mack truck going to hit someone and not being able to stop it, and so our goal with everything that we do is to stop it,' Davis said. In the three years that Davis and her family have been advocating, there have been medical breakthroughs, now she said they are just waiting for a cure. 'I remember thinking, how do we have nothing,' Davis said. 'Since that time, so in just over a couple of years, we have three approved treatments for EB, two of which could actually work for Hallie's type, depending. But we're getting there. I mean, we're making huge, incredible strides. The FDA has approved these things, so now people don't have to hear there's nothing we can do.' There are only a few tickets left for tonight's ball. If you're interested in purchasing those or just learning more about EB and the heroes for Hallie Grace organization, you can click or tap here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Business Upturn
a day ago
- Business Upturn
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
By GlobeNewswire Published on June 6, 2025, 23:41 IST Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) — First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
a day ago
- Yahoo
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on CONTACT: Savanna Doud Fight Colorectal Cancer 703.548.1225 savanna@ in to access your portfolio